164 related articles for article (PubMed ID: 34992039)
1. Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment.
Liang JJ; Yu WL; Yang L; Xie BH; Qin KM; Yin YP; Yan JJ; Gong S; Liu TY; Zhou HB; Hong K
Eur J Med Chem; 2022 Feb; 229():114081. PubMed ID: 34992039
[TBL] [Abstract][Full Text] [Related]
2. Sesterterpene MHO7 suppresses breast cancer cells as a novel estrogen receptor degrader.
Zhao Y; Zhao C; Lu J; Wu J; Li C; Hu Z; Tian W; Yang L; Xiang J; Zhou H; Deng Z; Huang J; Hong K
Pharmacol Res; 2019 Aug; 146():104294. PubMed ID: 31175940
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation.
Lu X; Teng Y; Lin X; Xiao M; Liu C; Chi X; Zhang Y; Luo G; Xiang H
Bioorg Chem; 2021 Apr; 109():104714. PubMed ID: 33618254
[TBL] [Abstract][Full Text] [Related]
4. Novel class of 7-Oxabicyclo[2.2.1]heptene sulfonamides with long alkyl chains displaying improved estrogen receptor α degradation activity.
Hu Z; Li Y; Xie B; Ning W; Xiao Y; Huang Y; Zhao C; Huang J; Dong C; Zhou HB
Eur J Med Chem; 2019 Nov; 182():111605. PubMed ID: 31437778
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationship study of a potent MHO7 analogue as potential anti-triple negative breast cancer agent.
Liang JJ; Yu WL; Yang L; Qin KM; Yin YP; Li D; Ni YH; Yan JJ; Zhong YX; Deng ZX; Hong K
Eur J Med Chem; 2022 Jun; 236():114313. PubMed ID: 35390712
[TBL] [Abstract][Full Text] [Related]
6. Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
Zhao C; Tang C; Li C; Ning W; Hu Z; Xin L; Zhou HB; Huang J
Bioorg Med Chem; 2021 Jun; 40():116185. PubMed ID: 33965842
[TBL] [Abstract][Full Text] [Related]
7. Dynamics-Based Discovery of Novel, Potent Benzoic Acid Derivatives as Orally Bioavailable Selective Estrogen Receptor Degraders for ERα+ Breast Cancer.
Zhang X; Wang Y; Li X; Wu J; Zhao L; Li W; Liu J
J Med Chem; 2021 Jun; 64(11):7575-7595. PubMed ID: 34056898
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of raloxifene derivatives as a selective estrogen receptor down-regulator.
Shoda T; Kato M; Fujisato T; Misawa T; Demizu Y; Inoue H; Naito M; Kurihara M
Bioorg Med Chem; 2016 Jul; 24(13):2914-2919. PubMed ID: 27185013
[TBL] [Abstract][Full Text] [Related]
9. A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.
Lu X; Huang A; Xiao M; Sun L; Mao J; Luo G; Xiang H
Bioorg Chem; 2020 Apr; 97():103666. PubMed ID: 32088420
[TBL] [Abstract][Full Text] [Related]
10. ER alpha selective chromone, isoxazolylchromones, induces ROS-mediated cell death without autophagy.
Kaushik S; Sanawar R; Lekshmi A; Chandrasekhar L; Nair M; Bhatnagar S; Santhoshkumar TR
Chem Biol Drug Des; 2019 Jul; 94(1):1352-1367. PubMed ID: 31066219
[TBL] [Abstract][Full Text] [Related]
11. Ridaifen-SB8, a novel tamoxifen derivative, induces apoptosis via reactive oxygen species-dependent signaling pathway.
Guo WZ; Shiina I; Wang Y; Umeda E; Watanabe C; Uetake S; Ohashi Y; Yamori T; Dan S
Biochem Pharmacol; 2013 Nov; 86(9):1272-84. PubMed ID: 23973528
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen and Fulvestrant Hybrids Showed Potency as Selective Estrogen Receptor Down-Regulators.
Shoda T; Kato M; Fujisato T; Demizu Y; Inoue H; Naito M; Kurihara M
Med Chem; 2017; 13(3):206-213. PubMed ID: 27494098
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators.
Shoda T; Kato M; Harada R; Fujisato T; Okuhira K; Demizu Y; Inoue H; Naito M; Kurihara M
Bioorg Med Chem; 2015 Jul; 23(13):3091-6. PubMed ID: 26003343
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of estrogen receptor-alpha and rearranged during transfection tyrosine kinase is associated with withaferin a-induced apoptosis in MCF-7 breast cancer cells.
Zhang X; Mukerji R; Samadi AK; Cohen MS
BMC Complement Altern Med; 2011 Oct; 11():84. PubMed ID: 21978374
[TBL] [Abstract][Full Text] [Related]
15. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
16. Yuanhuatine from Daphne genkwa selectively induces mitochondrial apoptosis in estrogen receptor α-positive breast cancer cells in vitro.
Zhang YY; Shang XY; Hou XW; Li LZ; Wang W; Hayashi T; Zhang Y; Yao GD; Song SJ
Planta Med; 2019 Nov; 85(16):1275-1286. PubMed ID: 31627219
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents.
Luo G; Chen M; Lyu W; Zhao R; Xu Q; You Q; Xiang H
Bioorg Med Chem Lett; 2017 Jun; 27(12):2668-2673. PubMed ID: 28460819
[TBL] [Abstract][Full Text] [Related]
18. Development of cell-permeable peptide-based PROTACs targeting estrogen receptor α.
Dai Y; Yue N; Gong J; Liu C; Li Q; Zhou J; Huang W; Qian H
Eur J Med Chem; 2020 Feb; 187():111967. PubMed ID: 31865016
[TBL] [Abstract][Full Text] [Related]
19. A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway.
Zhou J; Shen R; Liu J; Deng X; Xin L; Zhou HB; Huang J
Bioorg Med Chem; 2023 Mar; 82():117235. PubMed ID: 36905762
[TBL] [Abstract][Full Text] [Related]
20. Bergapten induces ER depletion in breast cancer cells through SMAD4-mediated ubiquitination.
Panno ML; Giordano F; Rizza P; Pellegrino M; Zito D; Giordano C; Mauro L; Catalano S; Aquila S; Sisci D; De Amicis F; Vivacqua A; Fuqua SW; Andò S
Breast Cancer Res Treat; 2012 Nov; 136(2):443-55. PubMed ID: 23053665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
